Skip to main content

Aspira Women's Health Inc.

For the period ended Mar 31, 2026. Filed May 15, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 15, 2026

AWHL$0.430.0%Stored close · as of Sep 19, 2025

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

​​Page
PART IFinancial Information1
Item 1Financial Statements (unaudited)1
​Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20251
​Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 20252
​Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the three months ended March 31, 2026 and 20253
​Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 20255
​Notes to Condensed Consolidated Financial Statements6
Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations26
Item 3Quantitative and Qualitative Disclosures About Market Risk37
Item 4Controls and Procedures38
PART IIOther Information39
Item 1Legal Proceedings39
Item 1ARisk Factors39
Item 2Unregistered Sales of Equity Securities and Use of Proceeds39
Item 3Defaults Upon Senior Securities39
Item 4Mine Safety Disclosures39
Item 5Other Information39
Item 6Exhibits40
SIGNATURES41

The following are registered and unregistered trademarks and service marks of Aspira Women’s Health Inc.: VERMILLIONSM*, ASPIRA WOMEN’S HEALTH*®, OVA1®, OVERA®, ASPIRA LABS®, OVACALC®, OVASUITESM*, ASPIRA GENETIXSM, OVA1PLUS*®, OVAWATCH®, ENDOCHECKSM*, ENDOINFORMTM, OVAINFORMTM, OVAINHERITSM, ASPIRA SYNERGY*®, OVA360SM*, ASPIRA IVDSM, AND YOUR HEALTH, OUR PASSION*®.

i

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.